{"id":"NCT01586364","sponsor":"Shionogi","briefTitle":"Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus","officialTitle":"Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05-08","primaryCompletion":"2008-11-21","completion":"2008-12-22","firstPosted":"2012-04-26","resultsPosted":"2013-06-28","lastUpdate":"2018-05-21"},"enrollment":301,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atrophy","Vaginal Diseases"],"interventions":[{"type":"DRUG","name":"Ospemifene 60Mg Oral Tablet","otherNames":["OsphenaÂ®"]}],"arms":[{"label":"Ospemifene 60 mg Oral Tablet","type":"EXPERIMENTAL"}],"summary":"The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus.","primaryOutcome":{"measure":"Incidence of Adverse Events (AEs)","timeFrame":"Week 13 (Phone Contact) to Week 56 (Visit 4)","effectByArm":[{"arm":"Treatment Arm = 60 mg Ospemifene","deltaMin":220,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":301},"commonTop":["Hot Flush","Urinary Tract Infection","Sinusitis"]}}